Competing interest
None
References
Aktoz M, Altay H, Aslanger E, Atalar E, Atar I, Aytekin V, et al.(2020). [Turkish Cardiology Association Consensus Report: COVID-19
Pandemic and Cardiovascular Diseases (May 13, 2020)]. Turk Kardiyol
Dern Ars 48: 1-87.
Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier
C, et al. (2020). QT Interval Prolongation and Torsade De Pointes
in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin.
Heart Rhythm.
Drici MD, & Clement N (2001). Is gender a risk factor for adverse drug
reactions? The example of drug-induced long QT syndrome. Drug Saf
24: 575-585.
Gonin JM, Kadrofske MM, Schmaltz S, Bastyr EJ, 3rd, & Vinik AI (1990).
Corrected Q-T interval prolongation as diagnostic tool for assessment of
cardiac autonomic neuropathy in diabetes mellitus. Diabetes Care
13: 68-71.
Hancox JC, Hasnain M, Vieweg WV, Crouse EL, & Baranchuk A (2013).
Azithromycin, cardiovascular risks, QTc interval prolongation, torsade
de pointes, and regulatory issues: A narrative review based on the study
of case reports. Ther Adv Infect Dis 1: 155-165.
Helfenbein ED, Zhou SH, Lindauer JM, Field DQ, Gregg RE, Wang JJ,
et al. (2006). An algorithm for continuous real-time QT interval
monitoring. J Electrocardiol 39: S123-127.
Jankelson L, Karam G, Becker ML, Chinitz LA, & Tsai MC (2020). QT
prolongation, torsades de pointes, and sudden death with short courses
of chloroquine or hydroxychloroquine as used in COVID-19: A systematic
review. Heart Rhythm.
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ,
et al. (2014). Neuraminidase inhibitors for preventing and treating
influenza in healthy adults and children. Cochrane Database Syst
Rev: CD008965.
The cardiotoxicity of antimalarials. [Online] Available from
https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf.
[Accessed: 2017].
Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et
al. (2020). Risk of QT Interval Prolongation Associated With Use of
Hydroxychloroquine With or Without Concomitant Azithromycin Among
Hospitalized Patients Testing Positive for Coronavirus Disease 2019
(COVID-19). JAMA Cardiol.
Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, Thompson M, et
al. (2020). Experience with Hydroxychloroquine and Azithromycin in the
COVID-19 Pandemic: Implications for QT Interval Monitoring. J Am Heart
Assoc: e017144.
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero
J, et al. (2020). Association of Treatment With
Hydroxychloroquine or Azithromycin With In-Hospital Mortality in
Patients With COVID-19 in New York State. JAMA.
Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, et
al. (2020). The Effect of Chloroquine, Hydroxychloroquine and
Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2
Infection. Circ Arrhythm Electrophysiol.
Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, et al.(2016). Hydroxychloroquine Use Is Associated With Decreased Incident
Cardiovascular Events in Rheumatoid Arthritis Patients. J Am Heart Assoc
5.
Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui
R, et al. (2011). Cardiovascular autonomic neuropathy in
diabetes: clinical impact, assessment, diagnosis, and management.
Diabetes Metab Res Rev 27: 639-653.
Tang C, Godfrey T, Stawell R, & Nikpour M (2012). Hydroxychloroquine in
lupus: emerging evidence supporting multiple beneficial effects. Intern
Med J 42: 968-978.
Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser
BR, et al. (2013). Development and validation of a risk score to
predict QT interval prolongation in hospitalized patients. Circ
Cardiovasc Qual Outcomes 6: 479-487.
Tripathy S, Dassarma B, Roy S, Chabalala H, & Matsabisa MG (2020). A
review on possible modes of actions of Chloroquine/ Hydroxychloroquine:
Repurposing against SAR-COV-2 (COVID 19) pandemic. Int J Antimicrob
Agents: 106028.
Wang C, Horby PW, Hayden FG, & Gao GF (2020). A novel coronavirus
outbreak of global health concern. Lancet 395: 470-473.
Global surveillance for COVID-19 caused by human infection with
COVID-19 virus. [Online] Available from
https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov).
[Accessed: April 20].
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. (2020). In
Vitro Antiviral Activity and Projection of Optimized Dosing Design of
Hydroxychloroquine for the Treatment of Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis.
Zengin R SZ, Karadağ N, Çuhadaroğlu Ç, Ergönül Ö, Kocagöz S. (2020).
Adverse Cardiac Events Related to Hydroxychloroquine Prophylaxis and
Treatment of COVID-19. Infect Dis Clin Microbiol 2: 24-26.
Ziegler D, Voss A, Rathmann W, Strom A, Perz S, Roden M, et al.(2015). Increased prevalence of cardiac autonomic dysfunction at
different degrees of glucose intolerance in the general population: the
KORA S4 survey. Diabetologia 58: 1118-1128.